⌕
Regeneron Pharmaceuticals · REGN · Nasdaq
Tenet 64 · Solid
Compare
$952.40−0.32%At closeTenet 64 · Solid
$952.40−3.07 (−0.32%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$951.01−1.39 (−0.15%)
After hours: Nov 16, 2026, 4:43 PM ET

Regeneron Pharmaceuticals (REGN) Institutional Ownership

13F filers reported holding 91.1% of Regeneron Pharmaceuticals (REGN) shares as of Jun 30, 2026, across 1,349 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Held by 13F filers
91.1%
Jun 30, 2026
13F filers
1,349
quarter ended Jun 30, 2026
13F value
$58.8B
94.3M shares

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Jun 30, 2026. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 1,349 13F filers for Jun 30, 2026, over shares outstanding implied from the current quote, measured 140 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Nov 4, 2026Pitofsky JasonSVP ControllerAcquired · Option exercise1,500$726.53↗
Nov 4, 2026Pitofsky JasonSVP ControllerAcquired · Option exercise1,478$644.54↗
Nov 4, 2026Pitofsky JasonSVP ControllerAcquired · Option exercise905$492.00↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Open-market sale439$939.57↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Open-market sale575$940.46↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Open-market sale982$941.58↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Open-market sale1,215$942.31↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Open-market sale529$943.53↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Open-market sale108$944.22↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Open-market sale35$945.61↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Open-market sale179$950.76↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Option exercise905Non-Qualified Stock Option (right to buy)—↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Option exercise1,478Non-Qualified Stock Option (right to buy)—↗
Nov 4, 2026Pitofsky JasonSVP ControllerDisposed · Option exercise1,500Non-Qualified Stock Option (right to buy)—↗
Nov 3, 2026MURPHY ANDREW JCo-Chief Scientific OfficerDisposed · Gift1,054—↗
Nov 3, 2026Zoghbi Huda YdirectorAcquired · Option exercise7,439$380.95↗
Nov 3, 2026Zoghbi Huda YdirectorDisposed · Open-market sale6,939$970.42↗
Nov 3, 2026Zoghbi Huda YdirectorDisposed · Open-market sale500$971.06↗
Nov 3, 2026Zoghbi Huda YdirectorDisposed · Option exercise7,439Non-Qualified Stock Option (right to buy)—↗
Nov 2, 2026Fenimore Christopher R.EVP Finance CFOAcquired · Option exercise6,000$381.92↗

* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Regeneron Pharmaceuticals do institutions hold?

13F filers reported holding 91.1% of Regeneron Pharmaceuticals' shares as of Jun 30, 2026, across 1,349 filers.

How many 13F filers hold Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals was held by 1,349 13F filers as of Jun 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.